Thermo Fisher has issued a number of white papers on genomics recently. Here's one titled, "Expert Interviews - Revolutionize Patient Care through Clinically Relevant Molecular Testing."
You can download it directly from this Linked In page. Click to 'enlarge' the article display box, then see a 'download' error at top right.
AI CORNER
Here's a Chat GPT summary:
In this expert-driven primer on clinically relevant molecular testing, leaders in molecular pathology and clinical microbiology weigh in on the expanding role of PCR-based diagnostics in infectious disease and pharmacogenomics. The publication underscores that while analytic and clinical validity are foundational, it is clinical utility—the test’s ability to guide meaningful treatment decisions—that ultimately determines value in modern lab medicine.
Syndromic panels, especially for infectious diseases like pneumonia, gastrointestinal infections, and STIs, are highlighted as transformative tools due to their speed, sensitivity, and multiplexing capabilities, though experts caution that panels must be tailored by patient population and setting. Cost-effectiveness and stewardship remain pivotal themes throughout. Experts such as Joseph Yao, MD, and Stella Antonara, PhD, emphasize the need for partnerships between laboratorians and clinicians to identify the most appropriate use cases, avoid overtesting, and guide payer policies.
Meanwhile, pharmacogenomics is positioned as a rising frontier: Sherin Shaaban, MD, PhD, explains how COVID-era lab infrastructure and advances in high-throughput platforms are accelerating PGx adoption, despite persistent barriers like clinician education and data interpretation challenges.
Across all interviews, the core message is clear: molecular testing is no longer just about lab innovation—it’s about targeted, collaborative implementation that improves outcomes, controls costs, and redefines diagnostic strategy in precision medicine.
